Article Versions Notes

Stracke S, Lange S, Bornmann S, Kock H, Schulze L, Klinger-König J, Böhm S, Vogelgesang A, von Podewils F, Föel A, et al. Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study. Journal of Clinical Medicine. 2020; 9(6):1919. https://doi.org/10.3390/jcm9061919

Stracke, Sylvia, Sandra Lange, Sarah Bornmann, Holger Kock, Lara Schulze, Johanna Klinger-König, Susanne Böhm, Antje Vogelgesang, Felix von Podewils, Agnes Föel, and et al. 2020. "Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study" Journal of Clinical Medicine 9, no. 6: 1919. https://doi.org/10.3390/jcm9061919

Stracke, S., Lange, S., Bornmann, S., Kock, H., Schulze, L., Klinger-König, J., Böhm, S., Vogelgesang, A., von Podewils, F., Föel, A., Gross, S., Wenzel, K., Wallukat, G., Prüss, H., Dressel, A., Kunze, R., Grabe, H. J., Langner, S., & Dörr, M. (2020). Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study. Journal of Clinical Medicine, 9(6), 1919. https://doi.org/10.3390/jcm9061919